Wershler, Laura. “Depo-Provera: Does this Contraceptive Choice Support the Health and Well-Being of Adolescents and Young Women?” Canadian Woman Studies/ les cahiers de la femme. Special Issue: Women’s Health and Well-Being, vol. 24, no. 1 (Fall 2004), pp. 105-107.
Related Results
Depo-Provera/Norpla…
Chronic use of depot medroxyprogesterone acetate may have an adverse effect on cardiovascular health, a small, nonrandomized study suggests.
The widely used, long-acting contraceptive sold as Depo-Provera and given as a 150-mg injection every 12 weeks inhibits ovarian follicle proliferation. This causes anovulati…
319 pregnant women with HIV participating in a perinatal HIV transmission study were referred to local clinics for contraceptive counselling and management and followed prospectively. Median time to sexual activity post-partum was two months. 72% (231) initiated hormonal contraceptive use at about three months post-partum (range 1-11 months) and used it for at least two months du…
In Anne Walch’s article, “Hormones and Menopause Revisited” Jun/July 04, the paragraph beginning “Premarin, also known as conjugated equilin estrogen (CEE) …” should have read: “Premarin, also known as conjugated equilin estrogen (CEE), is derived from pregnant mare’s urine. The estrogens in Premarin are perfect for a menopausal mare, but foreign to a human female. The same goes fo…
This study among 6,109 HIV-negative women recruited from family planning clinics who were using either Depo Provera or combined oral contraception in Uganda and Zimbabwe tested the women quarterly for HIV over 15-24 months. 213 women became HIV positive during the study. Neither hormonal contraceptive method was …
Most Popular
13 Job Interview Mistakes To Avoid
3 Questions No Job Seeker Ever Wants To Be Asked?
5 Regular Mistakes In Public Speaking
…
PHILADELPHIA — “Once again, we have proven that postmenopausal hormone therapy causes breast cancer,” said attorney James A. Morris of the firm Brent Coon & Associates, commenting on the latest verdict in the nationwide hormone replacement therapy litigation. A Philadelphia jury found Pfizer Inc. (NYSE: PFE) liable for failing to properly warn New Jersey plaintiff Merle Simon’s physicians of the breast cancer risk posed by Provera, the progestin half of hormone replacement therapy. Pfiz…
NEW YORK — Although contraceptive injection is widely used in mentally and physically disabled women, many of these patients are candidates for a much wider variety of contraceptive methods, according to …
OTTAWA, ONTARIO, May 11, 2006 (CCNMatthews via COMTEX) — The Society of Obstetricians and Gynaecologists of Canada (SOGC) today released new guidelines for Canadian healthcare professionals to provide clear recommendations on the use of the injectable contraceptive Depo-Provera(R) (Depot Medroxyproge…
